NCT06117657View on ClinicalTrials.gov

Safety and Efficacy Clinical Study of KL-HIV-Tri01 in the Treatment of HIV Infected Subjects

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

August 20, 2024

Study Completion Date

September 10, 2025

Conditions
HIV Infections
Interventions
DRUG

Low dose KL-HIV-Tri01

Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^11 vg/kg.

DRUG

Middle dose KL-HIV-Tri01

Subjects will be dosed with single dose of KL-HIV-Tri01 at 8.0x10\^11 vg/kg.

DRUG

High dose KL-HIV-Tri01

Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^12 vg/kg.

All Listed Sponsors
lead

Affiliated Hospital of Guangdong Medical University

OTHER

NCT06117657 - Safety and Efficacy Clinical Study of KL-HIV-Tri01 in the Treatment of HIV Infected Subjects | Biotech Hunter | Biotech Hunter